TrialBlood advances2025

Elritercept, a modified activin receptor IIA ligand trap, increased erythropoiesis and thrombopoiesis in a phase 1 trial.

Jennifer Lachey et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.